Gilead Sciences (GILD) is a great example of the science of Growth vs. Value as the stock sells for just 7x earnings.

Gilead Sciences (GILD) doesn’t have a new blockbuster yet, but at 8x earnings the stock is a true value.

GIlead Sciences’ (GILD) HIV and hepatitis C drugs continue to power the company. Now, what does GILD do for its next act?

Beating the street and increasing profit estimates sent Gilead Sciences (GILD) to an All-Time high.

Gilead Sciences (GILD) is such a good value, but does it have the growth to go higher?

GIlead Sciences (GILD) doubled sales last qtr, yet sells for only 10x earnings. Here’s my 2015 outlook on GILD.

Gilead Sciences (GILD) drug Sovaldi is a blockbuster, but the drug is perhaps too good for GILD stock. Here’s why.

With the market in a correction, Gilead Sciences’ (GILD) blockbuster earnings report has practically gone unnoticed.

Gilead Sciences (GILD) has an instant blockbuster drug in Sovaldi which will propel GILD’s profits. Here’s what I think it does for the stock.

Gilead’s (GILD) new drug will be a blockbuseter. GILD doubled this year and I think the stock could double again in two years.